Geron/GERN

$3.64

-1.88%
-
1D1W1MYTD1YMAX

About Geron

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

Ticker

GERN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Scarlett

Employees

141

Headquarters

Foster city, United States

Geron Metrics

BasicAdvanced
$2.14B
Market cap
-
P/E ratio
-$0.32
EPS
0.59
Beta
-
Dividend rate
$2.14B
0.5869
$4.05
$1.64
12.17M
3.159
14.136
33.049
-62.99%
-112.29%
-92.09%
9,014.179
8
8.616
-60.23%
13.07%
-2.15%

What the Analysts think about Geron

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
39.56% upside
High $6.00
Low $4.50
$3.64
Current price
$5.08
Average price target

Geron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-100%
Net income
$-51.9M
15.85%
Profit margin
0%
-100%

Geron Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.29%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.07
-$0.09
-$0.08
-$0.09
-
Expected
-$0.10
-$0.08
-$0.10
-$0.11
-$0.10
Surprise
-30%
8%
-18.64%
-14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Geron stock?

Geron (GERN) has a market cap of $2.14B as of April 14, 2024.

What is the P/E ratio for Geron stock?

The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of April 14, 2024.

Does Geron stock pay dividends?

No, Geron (GERN) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Geron dividend payment date?

Geron (GERN) stock does not pay dividends to its shareholders.

What is the beta indicator for Geron?

Geron (GERN) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Geron stock price target?

The target price for Geron (GERN) stock is $5.08, which is 39.56% above the current price of $3.64. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Geron stock

Buy or sell Geron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing